Independent, evidence-based peptide science intelligence. Our editorial team combines expertise in peptide chemistry, molecular pharmacology, and biotech industry analysis.
Argireline is called Botox in a bottle. But the science is more nuanced. Here is what the data actually shows about this peptide and what experienced formulators know.
The FDA will hold an advisory committee meeting in July 2026 to review 7 peptides for compounding pharmacy use, while removing 12 from the restrictive Category 2 bulks list. The move follows direct pressure from Health Secretary RFK Jr. and the MAHA movement, marking the most significant peptide regulatory shift in a decade.
Vedana Therapeutics emerges from stealth with $46M Series A to develop anti-PACAP antibody therapies for migraine prevention. Led by the veterans who built the CGRP drug class, the startup targets a neuropeptide pathway that could help the 50%+ of patients who don't respond to current treatments.
GHK-Cu is the most studied peptide in skincare, with over 170 published papers exploring how this copper-binding tripeptide repairs aging skin at the cellular level.
TearSolutions' Lacripep, a synthetic peptide derived from human tear protein, has won both Orphan Drug and Fast Track designations from the FDA for neurotrophic keratitis. Phase 2 dosing has begun.
Retatrutide is not FDA-approved for human use. Yet the experimental weight loss peptide is everywhere — TikTok, Instagram, online marketplaces. Here is what the black market craze reveals about the FDA's peptide blind spot.
The FDA will convene an advisory panel July 23–24 to evaluate whether certain peptides should become accessible through licensed compounding pharmacies. The decision could reshape the US peptide market and set a regulatory precedent.
